FCCC LOGO Faculty Publications
Tian CQ , Markman M , Zaino R , Ozols RF , McGuire WP , Muggia FM , Rose PG , Spriggs D , Armstrong DK , Gynecologic Oncology Grp Study; Gynecologic Oncology Grp Study
CA-125 Change After Chemotherapy in Prediction of Treatment Outcome Among Advanced Mucinous and Clear Cell Epithelial Ovarian Cancers A Gynecologic Oncology Group Study
Cancer. 2009 Apr;115(7) :1395-1403
PMCID: PMC 2743569   
Back to previous list
Abstract
BACKGROUND: There are limited data regarding unique clinical or laboratory features associated with advanced clear cell (CC) and mucinous (MU) epithelial ovarian cancers (EOC), particularly the relationship between CA-125 antigen levels and prognosis. METHODS: A retrospective review of 7 previously reported Gynecologic Oncology Group phase 3 trials in patients with stage III/IV EOC was conducted. A variety of clinical parameters were examined, including the impact of baseline and changes in the CA-125 level after treatment of CC and MU EOC on progression-free (PFS) and overall survival (OS). RESULTS: Clinical outcomes among patients with advanced CC and MU EOC were significantly worse when compared with other cell types (median PFS, 9.7 vs 7.0 vs 16.7 months, respectively, P < .001: median OS, 19.4 vs 11.3 vs 40.5 months, respectively, P < .001). Suboptimal debulking was associated with significantly decreased PFS and OS among both. Although baseline CA-125 values were lower in CC (median, 154 mu/mL) and MU (100 mu/mL), compared with other cell types (275 mu/mL), this level did not appear to influence outcome among these 2 specific subtypes of EOC. However, an elevated level of CA-125 at the end of chemotherapy was significantly associated with decreased PFS and OS (P < .01 for all). CONCLUSIONS: Surgical debulking status is the most important variable at prechemotherapy predictive of prognosis among advanced CC and MU EOC patients. Changes in the CA-125 levels at the end treatment as compared with baseline can serve as valid indicators of PFS and OS, and likely the degree of inherent chemosensitivity. Cancer 2009;115:1395-403. (C) 2009 American Cancer Society.
Notes
Tian, Chunqiao Markman, Maurie Zaino, Richard Ozols, Robert F. McGuire, William P. Muggia, Franco M. Rose, Peter G. Spriggs, David Armstrong, Deborah K. JOHN WILEY & SONS INC 422ME